Logo do repositório
 
Publicação

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

2023-11Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRose, Angela M.C.
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorSandonis Martín, Virginia
dc.contributor.authorMazagatos, Clara
dc.contributor.authorPetrović, Goranka
dc.contributor.authorBaruch, Joaquin
dc.contributor.authorDenayer, Sarah
dc.contributor.authorSeyler, Lucie
dc.contributor.authorDomegan, Lisa
dc.contributor.authorLaunay, Odile
dc.contributor.authorMachado, Ausenda
dc.contributor.authorBurgui, Cristina
dc.contributor.authorVaikutyte, Roberta
dc.contributor.authorNiessen, F Annabel
dc.contributor.authorLoghin, Isabela I.
dc.contributor.authorHusa, Petr
dc.contributor.authorAouali, Nassera
dc.contributor.authorPanagiotakopoulos, George
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorHorváth, Judit Krisztina
dc.contributor.authorHoward, Jennifer
dc.contributor.authorPozo, Francisco
dc.contributor.authorGallardo, Virtudes
dc.contributor.authorNonković, Diana
dc.contributor.authorDžiugytė, Aušra
dc.contributor.authorBossuyt, Nathalie
dc.contributor.authorDemuyser, Thomas
dc.contributor.authorDuffy, Róisín
dc.contributor.authorLuong Nguyen, Liem binh
dc.contributor.authorKislaya, Irina
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorGefenaite, Giedre
dc.contributor.authorKnol, Mirjam J.
dc.contributor.authorPopescu, Corneliu
dc.contributor.authorSoučková, Lenka
dc.contributor.authorSimon, Marc
dc.contributor.authorMichelaki, Stella
dc.contributor.authorReiche, Janine
dc.contributor.authorFerenczi, Annamária
dc.contributor.authorDelgado-Sanz, Concepción
dc.contributor.authorLovrić Makarić, Zvjezdana
dc.contributor.authorCauchi, John Paul
dc.contributor.authorBarbezange, Cyril
dc.contributor.authorVan Nedervelde, Els
dc.contributor.authorO’Donnell, Joan
dc.contributor.authorDurier, Christine
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorCastilla, Jesús
dc.contributor.authorJonikaite, Indrė
dc.contributor.authorBruijning-Verhagen, Patricia C.J.L.
dc.contributor.authorLazar, Mihaela
dc.contributor.authorDemlová, Regina
dc.contributor.authorWirtz, Gil
dc.contributor.authorAmerali, Marina
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorKunstár, Mihály Pál
dc.contributor.authorKissling, Esther
dc.contributor.authorBacci, Sabrina
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE-COVID-19 hospital study team
dc.contributor.authorVEBIS hospital study team
dc.contributor.authorMembers of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)
dc.date.accessioned2024-01-05T15:39:33Z
dc.date.available2024-01-05T15:39:33Z
dc.date.issued2023-11
dc.description.abstractIntroduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.pt_PT
dc.description.abstractKey public health message: 1. What did you want to address in this study? In order to understand how well the COVID-19 vaccine is performing in Europe against hospitalisation during the period when the SARS-CoV-2 Omicron variant was circulating, we investigated vaccine effectiveness using data from a multi-country study of complete and booster-dose COVID-19 vaccination among adults aged 20 years and over. 2. What have we learnt from this study? Between December 2021 and July 2022, vaccine effectiveness against hospitalisation with laboratory-confirmed SARS-CoV-2 was 43% for complete vaccination. With addition of an mRNA booster dose, effectiveness was 59% overall. It was higher when onset of illness was close to the date of the last vaccination, at 85% when last booster dose was 14–59 days before onset, at 70% for 60–119 days, and falling below 40% for 120–179 days. 3. What are the implications of your findings for public health? In European hospital settings in 2022, during the Omicron period, COVID-19 mRNA booster vaccine provided an improved benefit for preventing hospitalisation, particularly if disease onset was within 4 months of receiving the booster dose.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2023 Nov;28(47):2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187pt_PT
dc.identifier.doi10.2807/1560-7917.ES.2023.28.47.2300187pt_PT
dc.identifier.issn1560-7917
dc.identifier.urihttp://hdl.handle.net/10400.18/8871
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Center for Disease Prevention and Controlpt_PT
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectHospitalpt_PT
dc.subjectOmicronpt_PT
dc.subjectVEBIS- LOTE 1pt_PT
dc.subjectVacinapt_PT
dc.subjectEfetividadept_PT
dc.subjectCuidados de Saúdept_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.subjectEuropept_PT
dc.titleVaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue47pt_PT
oaire.citation.startPage2300187pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume28pt_PT
person.familyNameMachado
person.familyNameKislaya
person.familyNameGuiomar
person.givenNameAusenda
person.givenNameIrina
person.givenNameRaquel
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idA815-4295-F91D
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0001-5772-2416
person.identifier.orcid0000-0002-4563-6315
person.identifier.scopus-author-id56442728800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationcf6a6914-1de2-4c2a-96b1-9d617ca28a15
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublication.latestForDiscovery9743082d-bed6-4e5e-94f5-1d27bb037bb0

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Vaccine effectiveness against COVID-19 hospitalisation in adults  20 years during Omicron-dominant circulation.pdf
Tamanho:
770.82 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais